目的 研究细胞周期调控因子E2F-1和p16蛋白与宫颈上皮内瘤变及宫颈鳞癌的表达及其临床意义。方法 通过免疫组化SP法检测宫颈上皮内瘤变Ⅰ-Ⅱ级(CINⅠ-Ⅱ级)、宫颈上皮内瘤变Ⅲ级(CINⅢ级)、宫颈鳞癌各40例中E2F-1和p16蛋白的表达情况,并用20例慢性宫颈炎组织作对照。结果 E2F-1蛋白在CINⅠ-Ⅱ级、CINⅢ级和宫颈鳞癌组中阳性率分别为17.5%、67.5%和80.0%, 3组间有差异(χ²=37.278,P<0.001)。p16蛋白表达阳性率分别为27.5%、70.0%和82.5%,3组间差异有统计学意义(χ²=27.708, P<0.001)。CINⅠ-Ⅱ级与CINⅢ级组及宫颈鳞癌组比较均有差异,但CINⅢ级与宫颈鳞癌组间无差异。p16蛋白的表达与E2F-1蛋白表达有正相关关系;在鳞癌组中E2F-1与p16的异常表达与组织学分级、临床分期有关(P<0.05)。结论 子宫颈鳞癌的形成与E2F-1 、p16蛋白过表达是呈正相关关系,E2F-1 、p16 蛋白可能作为子宫颈鳞癌及CIN的标志物,对子宫颈癌筛查和预防有重要意义。

Objective To explore the clinicopathologic significance of the protein expression of cell cycle regulators E2F-1 and P16 in cervical intraepithelial neoplasia(CIN) and cervical squamous cell carcinoma(SCC). Methods Immunohistochemical technique S-P was used to determinate the expression of E2F-1 and P16 protein in 40 cases with CINⅠ-Ⅱ, 40 cases with CINⅢ and 40 cases with cervical squamous cell carcinoma. Results The positive rate of E2F-1 protein expression in CINⅠ-Ⅱ, CINⅢ and cervical squamous cell carcinoma was 17.5%,67.5% and 80.0%, respectively. There were significant differences among the three groups(χ²=37.278,P<0.001). The positive rate of P16 protein expression in CINⅠ-Ⅱ, CINⅢ and cervical squamous cell carcinoma was 27.5%,70.0% and 82.5%, respectively. There were significant differences among the three groups (χ²=27.708, P<0.001). The group with CINⅢ and cervical squamous cell carcinom compared with the group withCINⅠ-Ⅱ did have differences. But there were no significant differences in the group with CINⅢ and the group with cervical squamous cell carcinoma. The relative expressions between P16 and E2F-1 showed positive correlation. In the cervical squamous cell carcinoma group, the abnormal expression of E2F-1 and p16 were correlated with the histological grade and clinical stage. Conclusion It showed positive correlation between very high expression of p16 protein and E2F-1 infection in CIN and SCC. p16 protein and E2F-1 can be an indicator in SCC and CIN,which has very significance in preventing and screening of cervical cancer.

目的 评估CO₂激光治疗宫颈上皮内瘤变Ⅱ级（CIN2）病例的疗效。方法 收集2021年11月至2023年10月在本院行CO2激光治疗的92例CIN2患者的临床资料, 采用液基细胞学检查（LCT）和人乳头状瘤病毒（HPV）联合筛查随访,随访6~12个月, 任一结果异常者转诊阴道镜检查, 必要时行病理活组织检查（活检）观察鳞状上皮内病变情况。结果 92例CIN2患者中, 年龄25~45岁、有人工流产史、性伴侣人数3个及以上、因发现宫颈病变就诊者占比较多,患者均未生育。所有患者就诊时均发现HPV阳性, 20.65%患者报告HPV16阳性, HPV18阳性者占比1.09%, HPV其他12种阳性占60.87%, HPV16阳性伴其他12种阳性占17.39%。79例患者随访6个月后总HPV+LCT均阴率为74.68%（59/79）,LCT和HPV阴转率分别为92.41%（73/79）和74.68%（59/79）。所有患者术后12个月LCT均转阴。29例患者在术后12个月均无病变持续或病变发展。25岁以下患者术后6个月及12个月HPV持续率最低, 45~55岁患者术后HPV持续率最高,且多发生HPV16阳性及合并其他HPV亚型阳性的情况。结论 CO₂激光治疗可提高患者术后HPV与LCT阴转率, 所有患者术后6个月及12个月随访均无病变加重,且可明显改善年轻患者HPV感染情况。对于有生育要求且具备适应证的CIN2患者, 应积极采取CO₂激光治疗以获得更高健康收益。

Objective To evaluate the therapeutic efficacy of CO₂ laser treatment in cervical intraepithelial neoplasia grade 2（CIN2）patients. Methods We retrospectively analyzed data from 92 CIN2 patients who underwent CO₂ laser therapy at the institution from November 2021 to October 2023. Postoperative followed-up for 6-12 months, screening with liquid-based cytopathology test（LCT）and high-risk human papilloma virus（HPV）testing. Patients with abnormal results in either test were referred for colposcopy, with biopsy performed to evaluate residual or recurrent squamous intraepithelial lesions. Results Among total of 92 patients, most patients aged 25-45 years old, with a history of induced abortion, had three or more sexual partners, and visited hospital due to cervical lesions, and none of the patients gave birth. All patients were found to be HPV positive at hospital visits, with 20. 65% of HPV16 positive, 1. 09% of HPV18 positive, 60. 87% of other 12 kinds HPV positive, while HPV16 positive with other 12 kinds accounted for 17. 39%. Among the 79 patients after 6-month follow-up, the dual-negative conversion rate（HPV+LCT）was 74. 68%（59/79）, with LCT and HPV negative rates reaching 92. 41%（73/79）and 74. 68%（59/79）, respectively. After 12-month follow-up, all patients achieved LCT negativity, 29 patients with no documented lesion persistence or disease progression. Notably, patients aged <25 years exhibited the lowest postoperative HPV persistence rates between 6- to 12-month follow-up, whereas those aged 45-55 years demonstrated the highest persistence rates, frequently associated with HPV16 positivity or co-infection with other HPV subtypes. Conclusions CO₂ laser therapy significantly increases postoperative negative conversion rates for HPV and LCT. No lesion progression was observed in patients between 6- to 12-month follow-ups. The therapy also notably improves HPV clearance in younger patients. For patients with CIN2 who have fertility requirements and meet the indications, CO2 laser therapy should be actively adopted to achieve greater health benefits.